@article{oai:niigata-u.repo.nii.ac.jp:00008221,
 author = {近藤, 直樹 and 藤沢, 純一 and 工藤, 尚子 and 村井, 丈寛 and 遠藤, 直人},
 issue = {8},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Aug},
 note = {Rheumatoid arthritis (RA) is chronic and inflammatory autoimmune diseases. Biologics have been treated for refractory RA patients. In our facility, they have been used since 2001 and totally 702 cases by the end of August, 2016. Retention rates of each biologics in our facility were as follows; tocilizumab: 82% (1 year) and 75% (2-years), etanercept: 78% and 71%, infliximab: 70% and 61%, adalimumab: 67% and 54%, and then abatacept, certorizumab pegol, golimumab, in order. The clinical outcome of subcutaneously injected tocilizumab (TCZ-SC) was evaluated. TCZ-SC was administered for 40 patients with RA from 2013 through March 2016. The age was 62 years old on average (range; 24-86), disease duration of RA was 8 years on average (0.08-38 years). Biologics naive cases was 30 cases (75%). Methotrexate was used in 14 cases (35%) and prednisolone was used in 15 cases (38%), respectively. Disease activity score 28 (DAS28) was decreased from 4.72 before induction of TCZ-SC to 2.07 after 3 months, and 1.89 after 12 months. The DAS28 remission rate reached 76% just after 3 months and it was maintained to 81% after 12 months. TCZ-SC was ceased in 5 cases within the observation period. Of these, 4 cases were due to the adverse events and 1 was due to non-efficacy. In conclusion, total management is important for achieving tight control of RA patients by monitoring joint pain, swelling, and deformity with physical status, ultrasonography, or X-ray findings in the clinical settings.},
 pages = {449--452},
 title = {1 整形外科領域 （シンポジウム 各科領域における生物学的製剤の現況と展望, 第720回新潟医学会）},
 volume = {131},
 year = {2017}
}